Biosimilars up - but not yet running
This article was originally published in Scrip
Executive Summary
The EU framework for biosimilar medicines is working and delivering products, but they are not penetrating the market as quickly as generics firms had hoped. This was one of the key messages to emerge from a recent conference in London organised by the European Generic medicines Association (EGA).